EMN vs HUN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: EMN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EMN and HUN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EMN and HUN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eastman Chemical Company (NYSE: EMN) is a global specialty materials producer headquartered in Kingsport, Tennessee, organized into four segments: Advanced Materials (specialty films, plastics, and interlayers), Additives and Functional Products (coatings, inks, and performance additives), Chemical Intermediates (commodity and functional chemicals), and Fibers (cellulose acetate tow, largely for cigarette filters). Annual revenue runs around $9 billion, and the company has leaned into circular-economy positioning through its Kingsport methanolysis (molecular recycling) plant, which converts hard-to-recycle plastic waste back into raw materials and added roughly $60 million of incremental earnings in 2025.

Full EMN guide

Huntsman Corporation is a global manufacturer of differentiated and specialty chemicals organized into three segments: Polyurethanes (MDI, polyols and TPU used in insulation, automotive seating, adhesives, coatings and footwear), Performance Products (amines, surfactants and maleic anhydride for agriculture, energy, personal care and construction), and Advanced Materials (epoxy, phenoxy, acrylic and polyurethane formulations for aerospace, electronics and industrial uses). It is roughly the fourth-largest MDI producer worldwide, behind Wanhua Chemical, BASF and Covestro.

Full HUN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• EMN drivers: Molecular recycling ramp; Specialty mix and pricing.
• HUN drivers: Pending Olin merger; Polyurethanes and MDI cycle.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Eastman is cyclical and sensitive to global industrial demand, energy and raw-material costs, and destocking, all of which pressured 2025 and early 2026 results. For HUN, huntsman is deeply cyclical and was loss-making in 2025 and early 2026, with net debt leverage around 6.1x and credit ratings cut to below investment grade, so a prolonged downturn strains the balance sheet.

Pick EMN if you believe its drivers more; HUN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EMN and HUN guides.

EMN. Eastman trades around $71 per share with a market cap near $8 billion, well below prior highs, reflecting soft recent results and a cyclical backdrop. Q1 2026 sales fell about 5% to ~$2.18 billion and net earnings dropped to ~$107 million, though management guided Q2 adjusted EPS to roughly $1.70 to $1.90. The ~4.5% yield and mid-to-high-teens P/E frame it as a value and income name rather than a growth stock.

HUN. Huntsman is currently unprofitable on a trailing basis, so a positive P/E is not meaningful and investors lean on revenue, EBITDA and leverage. As of mid-2026 the stock traded around $10 to $11 with a 52-week range of roughly $7.30 to $16, and the dividend yield screened high partly because the price had fallen. With a merger agreed, valuation is best read against the Olin exchange ratio rather than standalone multiples.

Headline figures (approximate, JULY 2026): EMN shows revenue (ttm) ~$9.2B, market cap ~$7.9B, p/e ratio ~18.9, fy2025 adjusted eps ~$5.42; HUN shows revenue (fy2025) ~$5.7B, revenue (q1 2026) ~$1.42B, net loss (fy2025) ~$275M, diluted eps (fy2025) ~-$1.59.

EMN and HUN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined EMN and HUN exposure against your real portfolio. It is not an investment adviser.